<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450981</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-021-1</org_study_id>
    <nct_id>NCT02450981</nct_id>
  </id_info>
  <brief_title>Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a phase 1 study which carried out to to evaluate the safety,&#xD;
      pharmacokinetics and tolerability of multiple intravitreal injections of BCD-021(bevacizumab&#xD;
      biosimilar candidate manufactured by CJSC BIOCAD, Russia) when used in patients with&#xD;
      neovascular wet age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCD-021-1 is an open label, non-comparative, non-randomized, multicenter phase 1 clinical&#xD;
      study evaluating pharmacokinetics, safety and tolerability of multiple intravitreal&#xD;
      injections of BCD-021 (bevacizumab biosimilar, CJSC BIOCAD) when given in patients with&#xD;
      exudative (wet) age-related macular degeneration.&#xD;
&#xD;
      The study will enrol 10 patients with confirmed neovascular wet age-related macular&#xD;
      degeneration. Before inclusion into the active phase of the study, patients will undergo a&#xD;
      diagnostic examination during the screening period with a maximum duration of 28 days.&#xD;
&#xD;
      The principal part of the study includes the period from the first intravitreal injection and&#xD;
      until 28 days after the third intravitreal injection. The goal of this stage is to evaluate&#xD;
      pharmacokinetics, the safety and tolerability of multiple intravitreal injections of BCD-021&#xD;
      (CJSC BIOCAD, Russia) when used in patients with neovascular wet age-related macular&#xD;
      degeneration.&#xD;
&#xD;
      Extension phase of the study (month 4 - month 12) is required to assess the long-term effects&#xD;
      of the therapy and get full information about the immunogenicity of the study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to BCD-021 and appeared after the first, the second and the third intravitreal injection of BCD-021</measure>
    <time_frame>85 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of ocular and systemic AEs and SAEs related to age-related macular degeneration (AMD) therapy, appeared within the whole study period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases of early withdrawal from the study caused by AE or SAE</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero (0) hours to 28 days, maximum concentration and half life of bevacizumab after the first administration of BCD-021</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 56 days to 84 days, maximum concentration and half life of bevacizumab after the third administration of BCD-021</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of bevacizumab between the first and the third administration of BCD-021</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have binding and neutralizing antibodies to BCD-021 in serum at screening, after 3 intravitreal injections and after 12 intravitreal injections of BCD-021</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in visual acuity score, measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale at month 12</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fluid and foveal thickness on OCT during the study</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of visual improvement after initiation of therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>BCD-021 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (BCD-021)</intervention_name>
    <description>Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)</description>
    <arm_group_label>BCD-021 group</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subject has provided informed consent;&#xD;
&#xD;
          -  men and women;&#xD;
&#xD;
          -  patients must be from 50 years old;&#xD;
&#xD;
          -  wet AMD in the study eye, defined as active choroidal neovascular membrane (CNV) (not&#xD;
             previously treated with intravitreal injection of an anti-VEGF drug), including&#xD;
             retinal angiomatous proliferation (RAP), with oedema involving the fovea as&#xD;
             demonstrated with optical coherence tomography (OCT);&#xD;
&#xD;
          -  best corrected VA for the studied eye ranging between 20/32 (6.3/10) and 20/320&#xD;
             (0.6/10) with ETDRS scale;&#xD;
&#xD;
          -  size of lesion &lt; 12 disk area;&#xD;
&#xD;
          -  in case of occult neovessels, proof required of recent development of the lesion: loss&#xD;
             of VA of at least 5 letters ETDRS in the last 3 months OR appearance of a subretinal&#xD;
             hemorrhage OR increase in the size of the lesion (&gt; 10%) using fluorescein angiography&#xD;
             during the last month by comparison with the last 3 months OR appearance of OCT&#xD;
             criteria of macular oedema type, serous separation of neuro-epithelium, separation of&#xD;
             the pigmented epithelial during the last month before inclusion to trial;&#xD;
&#xD;
          -  only one eye of each study patient may be recruited into the study;&#xD;
&#xD;
          -  patient's ability to follow the protocol procedures;&#xD;
&#xD;
          -  male and female patients with normal reproductive function and their sexual partners&#xD;
             are aware and willing to use voluntarily reliable methods of contraception during the&#xD;
             whole period of the study including the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current treatment with intravitreal injection of an anti-VEGF drug&#xD;
             (ranibizumab, bevacizumab, aflibercept or pegaptanib, etc.);&#xD;
&#xD;
          -  Other healing treatment in the studied eye during the last 3 months before the first&#xD;
             injection;&#xD;
&#xD;
          -  Former vitrectomy in the study eye;&#xD;
&#xD;
          -  Medical history of photocoagulation in the studied eye;&#xD;
&#xD;
          -  Involvement in another clinical study (studied eye and/or the other eye);&#xD;
&#xD;
          -  Subretinal hemorrhage reaching the fovea centre, with a size &gt; 50% of the lesion area;&#xD;
&#xD;
          -  Fibrosis or retrofoveal retinal atrophy in the studied eye;&#xD;
&#xD;
          -  Retinal pigment epithelial tear reaching the macula in the studied eye;&#xD;
&#xD;
          -  Choroidal neovascularisation not related to a AMD in the studied eye;&#xD;
&#xD;
          -  Medical history of intravitreal medical device in the studied eye;&#xD;
&#xD;
          -  Active or suspected ocular or peri-ocular infection;&#xD;
&#xD;
          -  Acute conjunctivitis, keratitis, scleritis, or endophthalmitis;&#xD;
&#xD;
          -  Serious active intra-ocular inflammation in the studied eye;&#xD;
&#xD;
          -  Macula-foramen of the studied eye;&#xD;
&#xD;
          -  Myopia larger than -8 diopter;&#xD;
&#xD;
          -  Former corneal grafting of the studied eye;&#xD;
&#xD;
          -  Medical history of auto-immune or idiopathic uveitis;&#xD;
&#xD;
          -  Proved diabetic retinopathy;&#xD;
&#xD;
          -  Intra-ocular pressure â‰¥ 25 mmHg despite two topical hypotonic treatments;&#xD;
&#xD;
          -  Medical history of intra-ocular surgery within 2 months before the first injection in&#xD;
             the studied eye;&#xD;
&#xD;
          -  Aphakia or lack of lens capsule (not removed by laser) in the studied eye;&#xD;
&#xD;
          -  Any illness or ocular condition that would require an intra-ocular surgery in the&#xD;
             studied eye within 12 months after the inclusion;&#xD;
&#xD;
          -  Known hypersensitivity to bevacizumab or another drug composite of the medicinal&#xD;
             products used; allergy to anaesthetic eye drops;&#xD;
&#xD;
          -  Arterial hypertension that is not controlled by an appropriate treatment;&#xD;
&#xD;
          -  Previous or current treatment with systemic administration of bevacizumab;&#xD;
&#xD;
          -  Pregnancy and breast-feeding;&#xD;
&#xD;
          -  Any determined immunodeficiency;&#xD;
&#xD;
          -  Syphilis, HIV, hepatitis B, any history of hepatitis C virus;&#xD;
&#xD;
          -  Any mental disorder that can create a risk for the patient or influence the patient's&#xD;
             ability to follow the study protocol;&#xD;
&#xD;
          -  Drug addiction, alcoholism.&#xD;
&#xD;
          -  Presence or history of malignant neoplasm (including lymphoproliferative disease);&#xD;
&#xD;
          -  Simultaneous participation in any other clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>CJCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

